Issue link: https://maltatoday.uberflip.com/i/900922
maltatoday WEDNESDAY 15 NOVEMBER 2017 12 Business Today Regular market closed – 14/11/2017 Symbol Code Volume Traded Value Traded Trades High Price Low Price Open Price Close Price Change t BOV 121,787 213,669.11 29 1.765 1.750 1.765 1.751 -0.004 s GO 15,300 54,592.74 9 3.599 3.515 3.520 3.599 0.069 s HSB 49,529 91,646.63 10 1.852 1.850 1.850 1.852 0.002 t IHI 32,321 20,332.36 6 0.640 0.620 0.640 0.620 -0.010 l LOM 11,000 24,200.00 1 2.200 2.200 2.200 2.200 0.000 t MIA 470 2,185.50 1 4.650 4.650 4.650 4.650 -0.040 s MLT 5,000 3,800.00 1 0.760 0.760 0.760 0.760 0.009 t MPC 3,200 1,622.40 2 0.507 0.507 0.507 0.507 -0.003 s RS2 2,000 3,160.00 1 1.580 1.580 1.580 1.580 0.022 t G18A 15,141 15,937.42 2 105.260 105.260 105.260 105.260 -0.220 t G19A 6,989 7,824.19 1 111.950 111.950 111.950 111.950 -0.220 s G20A 1,165 1,321.58 1 113.440 113.440 113.440 113.440 0.440 t G20B 14,000 15,583.40 1 111.310 111.310 111.310 111.310 -0.180 t G21A 92,598 109,666.42 5 118.450 118.430 118.430 118.430 -0.020 t G22A 2,563 3,167.61 1 123.590 123.590 123.590 123.590 -0.210 t G22B 13,000 15,449.20 1 118.840 118.840 118.840 118.840 -0.230 t G23A 2,500 3,224.25 1 128.970 128.970 128.970 128.970 -0.350 s G28B 10,000 13,250.00 1 132.500 132.500 132.500 132.500 0.440 t G29B 60,000 65,622.00 2 109.370 109.370 109.370 109.370 -0.630 l G30A 2,500 3,561.00 1 142.440 142.440 142.440 142.440 0.000 s G31A 14,500 20,790.60 3 143.420 143.370 143.370 143.420 0.020 t G32A 20,000 27,524.00 2 137.630 137.590 137.590 137.630 -0.570 s G33A 9,500 12,738.65 2 134.110 134.070 134.070 134.110 0.040 t G34A 40,100 52,932.58 3 132.260 131.990 131.990 132.260 -0.740 s G35A 3,000 3,123.90 1 104.130 104.130 104.130 104.130 0.020 s G36A 107,500 116,432.59 5 108.390 108.110 108.110 108.290 0.170 s G39A 54,900 55,076.93 7 100.530 100.250 100.270 100.530 0.250 t G40A 48,600 56,222.40 5 115.900 115.600 115.600 115.700 -0.840 s G41A 89,500 93,226.45 5 104.230 104.010 104.230 104.230 0.050 s AX24A 4,100 4,551.00 1 111.000 111.000 111.000 111.000 0.500 t BV18A 26,000 26,065.50 4 100.400 100.000 100.400 100.000 -1.000 l BV30B 32,300 31,651.50 3 98.000 97.990 97.990 98.000 0.000 l HM24A 3,000 3,120.30 1 104.010 104.010 104.010 104.010 0.000 l HP25A 3,300 3,446.85 1 104.450 104.450 104.450 104.450 0.000 l IG24A 1,300 1,378.00 1 106.000 106.000 106.000 106.000 0.000 s IH25A 9,300 9,699.90 3 104.300 104.300 104.300 104.300 0.300 t MB27A 20,000 20,480.00 1 102.400 102.400 102.400 102.400 -0.090 l MF24A 25,500 27,160.05 2 106.510 106.510 106.510 106.510 0.000 l MI21A 2,500 2,560.00 1 102.400 102.400 102.400 102.400 0.000 l MI22A 7,200 7,452.00 1 103.500 103.500 103.500 103.500 0.000 s MS26A 12,900 13,354.08 1 103.520 103.520 103.520 103.520 0.020 t PT24A 38,600 39,022.67 5 101.750 101.000 101.750 101.020 -2.480 l SF27A 3,400 3,553.00 1 104.500 104.500 104.500 104.500 0.000 l ST27A 5,000 5,099.63 2 102.000 101.990 101.990 102.000 0.000 s TI24A 2,500 2,672.75 1 106.910 106.910 106.910 106.910 0.010 t VH24A 20,000 19,896.00 1 99.480 99.480 99.480 99.480 -0.020 Market Summary as at 14/11/2017 Equity Official List Session State ................................................................... Market Closed Number of trades ............................................................. 140 Volume Traded ................................................................. 1,065,563 Value of € denominated securities .................................... 1,329,047.14 Value of US$ denominated securities ................................ 0.00 Value of GBP£ denomi nated securities .............................. 0.00 Current Index ................................................................... - Previous Index ................................................................. - Change in Index (%) ......................................................... - Bank of Valletta plc ........................ 1.751 -0.23% Medserv plc .................................. 1.260 0.00% FIMBank plc .................................. 0.620 0.00% Mapfre Middlesea plc .................... 1.900 0.00% GlobalCapital plc ........................... 0.357 0.00% MIDI plc ........................................ 0.330 0.00% GO plc ........................................... 3.599 1.95% Plaza Centres plc ........................... 1.002 0.00% Grand Harbour Marina plc ............. 0.726 0.00% RS2 Software plc............................ 1.580 1.41% HSBC Bank Malta plc ..................... 1.852 0.11% Simonds Farsons Cisk plc ............... 9.500 0.00% International Hotel Investments plc 0.620 -1.59% Tigné Mall plc ................................ 0.960 0.00% Lombard Bank Malta plc ................ 2.200 0.00% Pefaco International plc ................. 2.240 0.00% Malita Investments plc ................... 0.760 1.20% Santumas Shareholdings plc ......... 2.250 0.00% Malta International Airport plc ....... 4.650 -0.85% Malta Properties Company plc ........ 0.507 -0.59% MaltaPost plc ................................. 2.079 0.00% PG plc ........................................... 1.480 0.00% MSE Index Biotech firms racing to recruit good gut bugs in war on cancer Biotech companies are compet- ing to develop medicines using "bugs as drugs" to fight cancer, building on the latest scientific findings that patients with high levels of good gut bacteria are more likely to respond to mod- ern immunotherapy. Certain bacteria seem to help in cancer by priming immune cells and smoothing the path for immunotherapy drugs known as PD-1 drugs that work by taking the brakes off the immune system. Seres Therapeutics hopes to become the first company to leverage this discovery through a collaboration with the MD Anderson Cancer Centre in Texas and the Parker Institute for Cancer Immunotherapy that will see its microbe medicine tested in a clinical trial. The Cambridge, Mass- achusetts-based firm has an exclusive option to license patent rights under the deal announced on Tuesday. MD Anderson scientists were among two groups of cancer researchers who reported on the benefits of good gut microbes in the journal Science earlier this month. The work underscores the importance of the microbiome - the vast community of microbes living inside us - which has been linked to everything from digestive disorders to depression. Seres Chief Executive Roger Pomerantz told Reuters the aim was to start the randomised, placebo-controlled clinical trial in metastatic melanoma in 2018, evaluating the impact of giving a newly developed Seres microbiome drug alongside a PD-1 therapy. There are currently two approved PD-1 drugs, Merck & Co's Keytruda or Bristol- Myers Squibb's Opdivo, but Pomerantz declined to say which would be used. Seres, which is backed by Swiss food giant Nestle, became the first microbiome drug developer to go public in June 2015 but it suffered a setback last year when its leading drug candidate failed in a trial against C. difficile, a debilitating gut infection. Beyond the gut Other companies are competing hard. Like Seres, some are also eyeing the new opportunity in cancer, as microbiome science moves beyond the initial focus on gastrointestinal conditions like C. difficile, ulcerative colitis and inflammatory bowel disease. Vedanta Biosciences, another US biotech firm that is an affiliate of PureTech Health, plans to file for approval to start a clinical trial in immuno- oncology in 2018, while Synlogic is also working on experimental cancer therapies. French biotech company Enterome, meanwhile, is working with Bristol-Myers on microbiome-derived diagnostic tests and potential drugs to use with the US drugmaker's immunotherapy medicines. Advocates argue that micro- biome medicine offers a smart way to both tone down the immune system response - useful for conditions like rheumatoid arthritis and allergies - or ramp it up, which is needed for the body to fight back against cancer. The first wave of microbiome drugs rely on faecal microbiota transplantation (FMT), or samples of microbes distilled from human faeces, delivered as a capsule or by enema. But companies are also working on synthetically fermented versions. Seres boss Pomerantz believes microbiome science will open up a major new treatment field, like mono- clonal antibodies did when they were pioneered by Cento- cor, now part of Johnson & Johnson, three decades ago. "Just as Centocor started monoclonals back in the 1980s, we think we are the Centocor of the microbiome - but of course there will be other companies." ...................................................... Breast cancer researchers find bacteria imbalance link